- Home
- ARVN vs IGR Comparison
ARVN vs IGR Comparison
Compare ARVN & IGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ARVN | IGR |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 781.0M | 645.2M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | ARVN | IGR |
|---|---|---|
| Price | $10.47 | $4.38 |
| Analyst Decision | Buy | |
| Analyst Count | 20 | 0 |
| Target Price | ★ $15.35 | N/A |
| AVG Volume (30 Days) | ★ 763.2K | 659.0K |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.93% |
| EPS Growth | ★ 58.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.90 | $4.20 |
| 52 Week High | $14.22 | $5.37 |
Technical Indicators
Market Signals| Indicator | ARVN | IGR |
|---|---|---|
| Relative Strength Index (RSI) | 29.80 | 30.45 |
| Support Level | $9.02 | $4.20 |
| Resistance Level | $14.03 | $4.38 |
| Average True Range (ATR) | 0.69 | 0.09 |
| MACD | -0.32 | -0.05 |
| Stochastic Oscillator | 2.36 | 9.68 |
Price Performance
Historical ComparisonAbout ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About IGR CBRE Global Real Estate Income Fund of Beneficial Interest
CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.